Replacing chemotherapy with olaparib alongside pembrolizumab did not improve the primary progression-free survival outcome in metastatic TNBC.
The registry lists NCT04191135 as terminated, last updated 2026-09-14. Enrolment is 462 actual participants. Interventions: Pembrolizumab, Olaparib, Carboplatin, Gemcitabine. Primary measures include Progression-Free Survival (PFS); Overall Survival (OS). The registry reason for stopping is: Business Reasons Results are posted in the registry. The primary paper reports 460 participants receiving induction and 271 randomised; these analysis populations differ from the registry total of 462. Median PFS was 5.5 versus 5.6 months (HR 0.98, 95% CI 0.72-1.33, p=0.4556), and OS 25.1 versus 23.4 months (HR 0.95, 95% CI 0.64-1.40). Exploratory tumour-BRCA subgroup estimates were imprecise and do not establish a positive subgroup trial.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
462 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival, randomised maintenance populationprimary | Pembrolizumab plus olaparib | - | 5.5 months | 0.98 (0.72 to 1.33) | 0.4556 | link |
| Pembrolizumab plus chemotherapy | - | 5.6 months | ||||
| Overall survival, randomised maintenance population | Pembrolizumab plus olaparib | - | 25.1 months | 0.95 (0.64 to 1.4) | - | link |
| Pembrolizumab plus chemotherapy | - | 23.4 months |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-08. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Olaparib, PARP, Breast cancer (all types).
Shares Olaparib, PARP, Triple-negative breast cancer (TNBC), Breast cancer (all types).
Shares Olaparib, PARP, Triple-negative breast cancer (TNBC), Breast cancer (all types).
Shares Olaparib, Triple-negative breast cancer (TNBC), Breast cancer (all types).
Shares Olaparib, PARP, Triple-negative breast cancer (TNBC), Breast cancer (all types).
Shares PARP, Triple-negative breast cancer (TNBC).
Shares PARP, Triple-negative breast cancer (TNBC), Breast cancer (all types).
Shares PARP, Triple-negative breast cancer (TNBC), Breast cancer (all types).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/